에 대한 최신 뉴스 BioNTech (NASDAQ:BNTX) 주식

BioNTech

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

Large Cap

News

Movers

Trading Ideas

ASND

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

$BTC

AVGO

EXAS

FSLR

MSTR

ORCL

ROKU

WOOF

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식은 회사가 $2억 3,500만의 순수익을 올렸다고 발표한 후 98.32% 급등했다.

츄이, 브로드컴 및 ARM은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 8일-9월 14일)

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Macro Economic Events

Mid Cap

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Small Cap

Treasuries

Econ #s

Economics

Federal Reserve

Tech

ETFs

ADTN

SPDR Dow Jones Industrial Average ETF Trust

FANG

JJSF

NVTS

PLTR

iShares Trust Barclays 20+ Year Treasury Bond Fund

XLRE

YUMC

글로벌 시장은 극심한 변동성을 겪고 있으며, 일본의 닛케이 225 지수가 밤새 13% 급락한 이후 월스트리트의 블랙 먼데이는 불가피한 것처럼 보였지만, 주가 지수는 뉴욕 정오 거래를 통해 장 초반 손실을 제한하려고 시도하고 있다.

미국 주식 시장은 서비스 지표의 확장에 블랙 먼데이의 하락을 축소, 채권 상승은 정체

BioNTech SE

WIIM

TNYA

Tenaya Therapeutics shares are trading higher after the company announced it dosed its first patient with TN-401 gene therapy in the RIDGE-1 Phase 1b clinical trial at the University of California, San Francisco.

ALAR

Alarum Technologies shares are trading lower. The company reported Q3 financial results.

Raymond James analyst Josh Beck reiterates Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Strong Buy and maintains $675 price target.

Price Target

Reiteration

Analyst Ratings

Raymond James Reiterates Strong Buy on Meta Platforms, Maintains $675 Price Target

Pseudonymous cryptocurrency trader Jelle shared his portfolio strategy in light of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) approaching $100,000 and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42139601/solana-hits-264-record-high-as-etf-filings-regulatory-optimism-drive-market-momentum">making a new all-time high.</a>
What Happened: The trader <a href="https://x.com/CryptoJelleNL/status/1860969575220740465">took</a> to X to outline his plans for capitalizing on the uptrend of major cryptocurrencies.
Bitcoin:
Gradually reducing BTC holdings by 1% weekly, increasing to 2% weekly after Bitcoin surpasses $100,000. This ensures exposure to gains while mitigating risk as volatility rises.
<ul>
<li>Taking profits with a 10% sell-off at peak levels, followed by 2% weekly reductions.</li>
</ul>
Solana:
Entered SOL at $20, sold 10% at the all-time high break and will continue reducing the position by 2% per week. 
Ethereum:
Plans to start taking 10% profits when ETH reaches new all-time highs and reduce his position 2$ per week subsequently.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42163156/why-bitcoins-rally-is-stalling-below-100000">Why Bitcoin's Rally Is Stalling Below $100,000</a>
Why It Matters: Jelle emphasizes reducing risk as markets grow more volatile, capitalizing on growth opportunities, and prioritizing profitable outcomes for this cycle. 
His approach encourages other traders to adopt disciplined strategies for managing gains and minimizing potential losses.
Key advice includes funneling profits directly into savings or reinvestment to secure financial wins. &#8220;It&#8217;s time to make some money. Let's make this cycle count,&#8221; Jelle concluded.
The global cryptocurrency market surpassed $3 trillion, with Bitcoin dominance at 57.8%, according to CoinMarketCap. The top ten crypto coins over the past 30 days (highest gains) include altcoins, meme coins and blockchain based tokens.
Among the top-performing cryptocurrencies over the past 30 days are: Peanut The Squirrel (CRYPTO: PNUT), Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) and The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>).
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155010/bitcoins-bull-run-betting-on-a-125k-finish-to-2024">Bitcoin&#8217;s Bull Run: Betting On A $125K Finish To 2024</a></li>
</ul>
Image: Shutterstock

$ADA

$DOGE

$ETH

$SAND

$SOL

$XLM

Bitcoin Below $100,000 — Veteran Trader Shares Profit-Taking Strategy

CRGO

Freightos shares are trading lower after the company reported Q3 financial results and issued Q4 revenue guidance with its midpoint below estimates.

Rumble shares are trading higher after the company announced that Dr. Disrespect will provide exclusive content to Rumble Premium and lead Rumble Gaming as an advisor.

Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed<a href="https://www.benzinga.com/news/24/09/41007173/cassava-sciences-stock-rises-on-interim-safety-review-of-simufilam-phase-3-trials"> by the market</a>.
Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock&#8217;s crash Sunday night.
What Happened: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, <a href="https://www.benzinga.com/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies">sending shares significantly lower </a>to start the trading week.
The company said it intends to present the data at an upcoming meeting, and Simufilam showed a favorable safety profile.
"Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease," the company said.
Cassava Sciences CEO Rick Barry called the results "disappointing for patients and their families."
Benzinga reached out to Cassava for comment.
Shkreli, a former hedge fund manager, predicted Monday's sharp shared decline.
"If you have $ on robinhood or interactive, short SAVA now," Shkreli <a href="https://x.com/MartinShkreli/status/1860886801617125798">tweeted </a>at 10:22 p.m. ET Sunday night.
The tweet signaled a belief that Cassava Sciences stock was set to fall. Robinhood and Interactive Brokers are among the brokers who offer 24-hour trading on select stocks, which is why they were named by Shkreli.
Shkreli was asked by several people on X if his tweet was financial advice, to which he replied yes. Shkreli also told people that waiting until Monday's opening bell at 9:30 a.m. ET would be too late to short the stock.
Cassava Sciences shares were halted at 7:25 a.m. ET with the company's update coming at 7:30 a.m. ET and shares resuming for trading at 7:55 a.m. ET.
Shares quickly fell Monday morning by over 80% after the company's update.
The post by Shkreli shouldn't come as a huge surprise since a Nov. 21 thread about a 38-page paper on Cassava by the former hedge fund manager is his pinned <a href="https://x.com/MartinShkreli/status/1859681514415607930">tweet</a>.
"I don't &#x2A;think&#x2A; it doesn't work. It is impossible for it to work," the thread says.
Shkreli said Alzheimer's Disease is a very tough market to target to begin with as 98% of the last Phase 3 trials for the disease have failed. Cassava's Phase 3 treating symptomatic patients could doom it, Shkreli predicted in the thread.
"Cassava bulls are looking for a ‘lotto ticket' return, but their chances are worse than the lotto."
Shkreli was extremely confident in his prediction, with a post <a href="https://x.com/MartinShkreli/status/1860878868028269051">listing </a>the things that he would do if the Phase 3 trial met its primary endpoint.
<ol>
<li>Delete my X account</li>
<li>Shave my head on YouTube and delete that account as well</li>
<li>Begin estrogen therapy and legally change my name to Martina</li>
<li>Move to Haiti, bringing my best friend/cat Nibbles</li>
<li>Retire from business completely</li>
</ol>
Shkreli took aim at WallSteetBets, a subreddit on Reddit Monday with a <a href="https://x.com/MartinShkreli/status/1861031460586831913">tweet </a>saying that "garbage like $SAVA" comes from the subreddit.
Read Also: <a href="https://www.benzinga.com/insights/options/24/11/41817544/looking-at-cassava-sciencess-recent-unusual-options-activity">Looking At Cassava Sciences&#8217;s Recent Unusual Options Activity</a>
Why It's Important: Shkreli said Cassava not meeting the primary endpoint would make the stock "an easy short" and shares could trade near their cash value levels of $2 to $3 per share.
The prediction from Shkreli comes after the former hedge fund manager's wild past in the pharmaceutical sector. Known as "pharma bro" to many, Shkreli previously was CEO of Retrophin and Turing Pharmaceuticals. Shkreli <a href="https://www.benzinga.com/government/21/11/23904774/wall-street-crime-and-punishment-martin-shkreli-the-self-destructive-pharma-bro">famously raised the price</a> of antiparasitic drug Daraprim from $13.50 to $750 for insurance providers after Turing acquired the drug.
Shkreli was convicted of securities fraud in 2017 and currently has<a href="https://www.benzinga.com/news/24/10/41222384/pharma-bro-martin-shkreli-loses-appeal-supreme-court-imposes-65m-fine-issues-lifetime-ban-from-pharm"> a lifetime ban</a> from the pharmaceutical sector.
Before his recent Cassava Sciences focus, the former hedge funder has been making recent headlines in <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40185861/djt-trumpcoin-allegedly-launched-by-martin-shkreli-with-barron-trumps-help-tanks-98" target="_blank" rel="noopener">the cryptocurrency sector</a>.
Benzinga reached out to Shkreli for comment and did not hear back by the time of publication.
Citron Research, known for their short reports, praised Shkreli's prediction on Cassava Sciences in a <a href="https://x.com/CitronResearch/status/1861043591369429143">tweet</a>.
"$SAVA illustrates the difficulty in shorting stocks. Has been a clear fraud for years but almost became an impossible short because of the ‘new market forces'. Nice to see some good homework by @martinshkreli added with a dose of reality to achieve real price discovery," Citron Research tweeted.
SAVA Price Action: Cassava Sciences stock is down 84.6% to $4.06 on Monday versus a previous 52-week trading range of $8.79 to $42.20, hitting new 52-week lows.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre">SEC Charges Cassava Sciences Over Manipulated Alzheimer&#8217;s Trial Data, Company And Former Execs Agree To Pay Penalty</a></li>
</ul>
Photo: Wikimedia

Health Care

SAVA

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Raymond James analyst Brian MacArthur maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Outperform and lowers the price target from $26 to $25.

GOLD

Raymond James Maintains Outperform on Barrick Gold, Lowers Price Target to $25

Schneider National, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>), a premier multimodal provider of transportation, intermodal and logistics services, announced today the company, through certain wholly owned subsidiaries, has entered into a definitive agreement to acquire Cowan Systems, LLC and affiliated entities (collectively, "Cowan Systems"), for a cash purchase price of approximately $390 million, subject to certain adjustments. The sale includes separate agreements to purchase certain real estate assets relating to Cowan Systems' business for approximately $31 million in cash.

SNDR

Schneider's Has Entered Into A Definitive Agreement To Acquire Cowan Systems And Affiliated Entities, For A Cash Purchase Price Of ~$390M

Scotiabank analyst Nicholas Yulico maintains Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) with a Sector Outperform and raises the price target from $119 to $126.

Scotiabank Maintains Sector Outperform on Federal Realty Investment, Raises Price Target to $126

Scotiabank analyst Greg McGinniss maintains Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) with a Sector Perform and raises the price target from $23 to $26.

Scotiabank Maintains Sector Perform on Kimco Realty, Raises Price Target to $26

Raymond James analyst Brian MacArthur maintains Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) with a Outperform and lowers the price target from $62 to $59.

Raymond James Maintains Outperform on Newmont, Lowers Price Target to $59

United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect United Maritime to report an earnings per share (EPS) of $-0.05.
The announcement from United Maritime is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Here's a look at United Maritime's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.09</td>
<td>-0.13</td>
<td>-0.07</td>
<td>0.95</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<h3>United Maritime Share Price Analysis</h3>
Shares of United Maritime were trading at $2.08 as of November 22. Over the last 52-week period, shares are down 13.33%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/USEA/earnings">To track all earnings releases for United Maritime visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

USEA

A Look Ahead: United Maritime's Earnings Forecast

Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) will release its quarterly earnings report on Tuesday, 2024-11-26. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Icecure Medical to report an earnings per share (EPS) of $-0.07.
The market awaits Icecure Medical's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.01 in the last quarter, leading to a 0.98% drop in the share price on the following day.
Here's a look at Icecure Medical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732550465_0.png" alt="eps graph" />
<h3>Market Performance of Icecure Medical's Stock</h3>
Shares of Icecure Medical were trading at $0.7122 as of November 22. Over the last 52-week period, shares are down 39.48%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ICCM/earnings">To track all earnings releases for Icecure Medical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICCM

What to Expect from Icecure Medical's Earnings

Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $47.75, a high estimate of $48.00, and a low estimate of $47.00. Marking an increase of 3.8%, the current average surpasses the previous average price target of $46.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732550464_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Select Medical Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Select Medical Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Select Medical Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Select Medical Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SEM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Select Medical Hldgs analyst ratings.</a>
<h2>Delving into Select Medical Hldgs's Background</h2>
Select Medical Holdings Corp is a healthcare company that operates through four main segments: critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and Concentra institutions. Critical illness recovery hospitals and rehabilitation centres are designed for patients requiring extended recovery time with medical services. These two sectors combined compose roughly half of the total revenue and include over 103 critical illness recovery hospitals and inpatient rehab facilities. The outpatient rehabilitation segment includes over 1,928 rehabilitation clinics. The Concentra segment includes over 540 occupational health centers and 147 onsite clinics. The company is headquartered in Pennsylvania, and it operates across the United States.
<h3>Breaking Down Select Medical Hldgs's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Select Medical Hldgs's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 5.73%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Select Medical Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Select Medical Hldgs's ROE excels beyond industry benchmarks, reaching 3.21%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.67%, the company showcases effective utilization of assets.
Debt Management: Select Medical Hldgs's debt-to-equity ratio is below the industry average at 2.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For Select Medical Hldgs

Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-26. Here's what investors need to know before the announcement.
Analysts estimate that Ucloudlink Group will report an earnings per share (EPS) of $-0.01. 
Ucloudlink Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.06, leading to a 3.5% drop in the share price on the subsequent day.
Here's a look at Ucloudlink Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.01</td>
<td>-0.01</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.03</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-8.0%</td>
<td>-2.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732550457_0.png" alt="eps graph" />
<h3>Ucloudlink Group Share Price Analysis</h3>
Shares of Ucloudlink Group were trading at $1.24 as of November 22. Over the last 52-week period, shares are down 41.23%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/UCL/earnings">To track all earnings releases for Ucloudlink Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Ucloudlink Group's Upcoming Earnings Report

MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.09, a high estimate of $56.00, and a low estimate of $43.00. A 4.59% drop is evident in the current average compared to the previous average price target of $53.55. 
<img src="https://www.benzinga.com/files/images/story/2024/1732550456_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of MGM Resorts Intl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$54.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$56.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Carlo Santarelli</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MGM Resorts Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MGM Resorts Intl compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of MGM Resorts Intl's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MGM Resorts Intl's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MGM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MGM Resorts Intl analyst ratings.</a>
<h2>Delving into MGM Resorts Intl's Background</h2>
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 62% of total EBITDAR in 2023. MGM also owns US regional assets, which represented a low 20s share of 2023 EBITDAR (MGM's Macao EBITDAR was 17% of the total in 2023). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a new property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.
<h3>MGM Resorts Intl's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, MGM Resorts Intl showcased positive performance, achieving a revenue growth rate of 5.28% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: MGM Resorts Intl's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.41%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): MGM Resorts Intl's ROE stands out, surpassing industry averages. With an impressive ROE of 5.72%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): MGM Resorts Intl's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.44%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 9.9, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

11 Analysts Assess MGM Resorts Intl: What You Need To Know

Across the recent three months, 4 analysts have shared their insights on Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.75, a high estimate of $16.00, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 17.02% from the previous average price target of $11.75.
<img src="https://www.benzinga.com/files/images/story/2024/1732550448_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sally Beauty Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$12.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sally Beauty Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sally Beauty Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sally Beauty Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Sally Beauty Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SBH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sally Beauty Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Sally Beauty Holdings</h2>
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. Sally Beauty operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Colombia, Mexico, Peru, France, Ireland, Spain, Germany, and the Netherlands. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. Product offerings include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
<h3>Key Indicators: Sally Beauty Holdings's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Sally Beauty Holdings showcased positive performance, achieving a revenue growth rate of 1.48% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Sally Beauty Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.14%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sally Beauty Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sally Beauty Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 1.74%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Sally Beauty Holdings's debt-to-equity ratio surpasses industry norms, standing at 2.54. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Sally Beauty Holdings Stands With Analysts

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect MediWound to report an earnings per share (EPS) of $-0.44.
The announcement from MediWound is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.24 in the last quarter, leading to a 4.01% increase in the share price on the following day.
Here's a look at MediWound's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.44</td>
<td>-0.41</td>
<td>-0.23</td>
<td>-0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.68</td>
<td>-0.39</td>
<td>-0.19</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732550447_0.png" alt="eps graph" />
<h3>Performance of MediWound Shares</h3>
Shares of MediWound were trading at $16.48 as of November 22. Over the last 52-week period, shares are up 96.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDWD/earnings">To track all earnings releases for MediWound visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MDWD

Earnings Preview: MediWound

American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-26. Here's what investors need to know before the announcement.
Analysts estimate that American Woodmark will report an earnings per share (EPS) of $2.37. 
The market awaits American Woodmark's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.51, leading to a 0.99% drop in the share price on the subsequent day.
Here's a look at American Woodmark's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.40</td>
<td>1.78</td>
<td>1.29</td>
<td>2.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.89</td>
<td>1.70</td>
<td>1.66</td>
<td>2.36</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
<td>15.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732550437_0_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of American Woodmark were trading at $97.24 as of November 22. Over the last 52-week period, shares are up 42.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on American Woodmark</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on American Woodmark.
With 4 analyst ratings, American Woodmark has a consensus rating of Outperform. The average one-year price target is $111.0, indicating a potential 14.15% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Quanex Building Prods, Apogee Enterprises and Janus Intl Gr, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Quanex Building Prods is favoring an Buy trajectory, with an average 1-year price target of $38.0, suggesting a potential 60.92% downside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Apogee Enterprises, with an average 1-year price target of $75.0, implying a potential 22.87% downside.</li>
<li>The consensus among analysts is an Neutral trajectory for Janus Intl Gr, with an average 1-year price target of $10.4, indicating a potential 89.3% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary presents essential metrics for Quanex Building Prods, Apogee Enterprises and Janus Intl Gr, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Woodmark</td>
<td>Outperform</td>
<td>-7.85%</td>
<td>$92.87M</td>
<td>3.25%</td>
</tr>
<tr>
<td>Quanex Building Prods</td>
<td>Buy</td>
<td>-6.44%</td>
<td>$70.90M</td>
<td>4.37%</td>
</tr>
<tr>
<td>Apogee Enterprises</td>
<td>Neutral</td>
<td>-3.18%</td>
<td>$97.32M</td>
<td>6.20%</td>
</tr>
<tr>
<td>Janus Intl Gr</td>
<td>Neutral</td>
<td>-17.85%</td>
<td>$91.20M</td>
<td>2.18%</td>
</tr>
</tbody>
</table>

Key Takeaway:
American Woodmark ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks in the middle for Return on Equity.
<h3>Unveiling the Story Behind American Woodmark</h3>
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
<h3>Key Indicators: American Woodmark's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: American Woodmark's revenue growth over a period of 3 months has faced challenges. As of 31 July, 2024, the company experienced a revenue decline of approximately -7.85%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: American Woodmark's net margin is impressive, surpassing industry averages. With a net margin of 6.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): American Woodmark's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.25%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.84%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.57, American Woodmark adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/AMWD/earnings">To track all earnings releases for American Woodmark visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMWD

What's Next: American Woodmark's Earnings Preview

Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of mult...

BioNTech initiated with a Buy at Berenberg

Evercore ISI upgraded BioNTech (BNTX) to Outperform from In Line with a price target of $125, up from $110. The firm says it has been "growing incr...

BioNTech upgraded to Outperform from In Line at Evercore ISI

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Workday initiated, Kraft Heinz downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Walmart (WMT) provided a "beat and rai...

Walmart higher, Lowe's lower after earnings: Morning Buzz

BioNTech started at buy, Moderna at hold by Berenberg

CDC warns against a spike in COVID, flu cases

CDC warns of an imminent spike in COVID, flu cases

Johns Hopkins surgeon and writer Martin Makary is expected to be selected by President-elect Donald Trump to head the U.S. FDA, Reuters' Stephanie ...

Trump expected to pick Martin Makary to head FDA, Reuters reports

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: Trump Media considers developing crypto payment service

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target ...

Morgan Stanley Remains a Buy on BioNTech SE (BNTX)

AAPL

ABBV

ACRS

ADSK

AMZN

APLS

ASAN

BERY

BITF

BLNK

CART

CHPT

CMXHF

CSLLY

GOOG

GOOGL

IIIV

INCY

INTC

INTU

ISRG

JNPR

JOBY

MNDY

MRNA

MSFT

NVAX

OKTA

PCVX

SABR

SHOO

SMCI

SNEJF

SONY

UBER

VEEV

WDAY

Press Releases

BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024

Comments

BioNTech

뉴스

에 대한 최신 뉴스 BioNTech (NASDAQ:BNTX) 주식

월요일, 9월 23, 2024

일요일, 9월 15, 2024

월요일, 8월 05, 2024

일요일, 6월 23, 2024

일요일, 5월 26, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌